Arthur awarded endowed chair
Douglas Arthur, MD, associate director for clinical affairs and vice chair of the Department of Radiation Oncology, has been awarded the Natalie N. and John R. Congdon, Sr. Endowed Chair in Cancer Research, in recognition of his significant, ongoing contributions to VCU Massey Cancer Center’s research mission.
Holding the promise to improved health care
Electronic health records (EHRs) hold the promise to improve primary health care for millions of patients. However, enhancing current EHR functionality is needed to better support primary care clinicians and patients, according to a recent article.
Newly discovered signaling pathway could impact a variety of autoinflammatory diseases
Researchers from Massey have discovered a new signaling pathway in sterile inflammation that could impact the treatment of diseases such as cancer, multiple sclerosis and rheumatoid arthritis. Their findings offer insight into the role that activation of interferon-regulatory factor 1 (IRF1), a protein that functions as a transcriptional activator of a variety of target genes, plays in the production of chemokines and the recruitment of mononuclear cells to sites of sterile inflammation.
VCU Massey researcher works to develop new cancer-fighting drugs and target therapies
Matthew Hartman, Ph.D., has focused his research on two hot topics in the arena of cancer research: developing drugs that inhibit key cancer proteins and developing better ways to target cancer tumors. He studies how proteins interact with each other on the molecular level.
VCU researchers show experimental drug could enhance the effectiveness of existing multiple myeloma and myeloid leukemia therapies
A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies. The study, recently published in the journal Molecular Cancer Therapeutics, showed that dinaciclib disrupted a cell survival mechanism known as the unfolded protein response (UPR). Without the UPR, multiple myeloma and myeloid leukemia cells were unable to combat damage caused by some anti-cancer agents.